Esperion Therapeutis.Inc. buy Bankster
Summary
This prediction ended on 03.04.23 with a price of €1.43. Massive losses of -65.91% were the result for the BUY prediction by Bankster. Bankster has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Esperion Therapeutis.Inc. | 5.342% | 5.342% | 14.716% |
iShares Core DAX® | 1.663% | 6.945% | 18.807% |
iShares Nasdaq 100 | 1.261% | 4.883% | 23.667% |
iShares Nikkei 225® | 0.654% | 10.007% | 15.047% |
iShares S&P 500 | 1.403% | 4.350% | 23.305% |
Comments by Bankster for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Bankster for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
25.03.24
25.03.25
29.03.24